GlobeNewswire Inc.··Not SpecifiedIntellia Therapeutics Raises $180M in Stock Offering to Fuel CRISPR Pipeline
Intellia Therapeutics raises $180M via stock offering at $10.75/share to advance CRISPR gene-editing therapies, with lead underwriters Jefferies, Goldman Sachs, Citigroup.
REGNNTLApublic offeringcapital raise